CRST’s scientific team contributed in a study evaluating an ASO in mild Alzheimer’s disease A recently published phase Ib study in the journal Nature Medicine reported that intrathecal administration of a Tau-targeting antisense oligonucleotides (ASO), MAPTRx, resulted in sustained reduction…
Recent Posts
- LINK Medical AS acquires Finnish clinical research service company CRST Oy.
- CRST and Kancera AB signed a contract for a First-in-human trial with KAND145
- CRST has appointed Petri Vainio as the CRST’s new Chief Scientific Officer
- CRST’s scientific team contributed in a study evaluating an ASO in mild Alzheimer’s disease
- Lihavuuden lääkehoidossa kohti mullistusta
Recent Comments
No comments to show.